Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen

Clinical Therapeutics

Volumn 29, Issue 6, 2007, Pages 1203-1213

  Rascati, Karen L ^a   Akazawa, Manabu ^b   Johnsrud, Michael ^a   Stanford, Richard H ^c   Blanchette, Christopher M ^c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

chronic obstructive pulmonary disease; COPD; emergency department visit; hospitalization; initial medication regimen; Medicaid; treatment cost

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; SALMETEROL;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; EMERGENCY WARD; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LOGISTIC REGRESSION ANALYSIS; MEDICAID; PRESCRIPTION; STATISTICAL SIGNIFICANCE; UNITED STATES;

ADRENAL CORTEX HORMONES; ADULT; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; IPRATROPIUM; MALE; MEDICAID; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TEXAS; TREATMENT OUTCOME;

EID: 34547561144     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.06.006     Document Type: Article

References (16)

1. Available at: http://www.goldcopd.com/Guidelineitem.asp?|1=2&vb2=1&intld=989. Accessed January 5, 2007. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2006)
2. Mannino D., Homa D., Akinbami L., et al. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ 51 (2002) 1-16
3. American Lung Association. Trends in chronic bronchitis and emphysema: Morbidity and mortality (2003), Epidemiology & Statistics Unit, New York, NY
4. Strassels S., Smith D., Sullivan S., and Mahajan P. The costs of treating COPD in the United States. Chest 119 (2001) 344-352
5. Halpern M., Stanford R., and Borker R. The burden of COPD in the U.S.A.: Results from the Confronting COPD survey. Respir Med 97 Suppl C (2003) S81-S89
6. Rascati K., Stanford R., and Borker R. A comparison of the risk of hospitalizations due to chronic obstructive pulmonary disease in Medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. Clin Ther 27 (2005) 346-354
7. Kiri V., Bettoncelli G., Testi R., and Viegi G. Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA. Respir Med 99 (2005) 1115-1124
8. Gartlehner G., Hansen R., Carson S., and Lohr K. Efficacy and safety of inhaled corticosteroids in patients with COPD: A systematic review and meta-analysis of health outcomes. Ann Fam Med 4 (2006) 253-262
9. for the TORCH investigators. Calverley P., Anderson J., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
10. Deyo R., Cherkin D., and Ciol M. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
11. Marton J., Boulanger L., Friedman M., et al. Assessing the costs of chronic obstructive pulmonary disease: The state Medicaid perspective. Respir Med 100 (2006) 996-1005
12. Sin D., McAlister F., Man S., and Anthonisen N. Contemporary management of chronic obstructive pulmonary disease: Scientific review. JAMA 290 (2003) 2301-2312
13. Donaldson G., and Wedzicha J. COPD exacerbations. 1: Epidemiology. Thorax 61 (2006) 164-168
14. Pauwels R., Calverley P., Buist A., et al. COPD exacerbations: The importance of a standard definition. Respir Med 98 (2004) 99-107
15. Rosenbaum P., and Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 70 (1983) 41-55
16. Schneeweiss S., and Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58 (2005) 323-337